ONE-WAYOngoing theme · still written in the latest filings
Development of KRP-S124, an OSA treatment candidate introduced from Bayer
An individual pharmaceutical development theme involving the acquisition from Bayer of exclusive worldwide rights to manufacture, develop, and sell KRP-S124, a candidate treatment for obstructive sleep apnea (OSA), and preparations for a Phase II clinical trial.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.
PeriodFY2025 →Still being written about.
Directionhelps1 helps · 0 hurts · 0 flat